Treatment of multiresistant Gram positive endocarditis;La terapia delle endocarditi da Gram positivi multiresistenti

Infezioni in Medicina

Volumn 17, Issue SUPPL. 3, 2009, Pages 13-24

  Utili, Riccardo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Daptomycin; Endocarditis; Enterococci; MRSA

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CREATINE KINASE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; NAFCILLIN; OXACILLIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DRUG EFFICACY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; GRAM POSITIVE INFECTION; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 77949762857     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Murdoch D.R., Corey G.R., Hoen B., et al. and the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch. Intern Med. 169 (5), 463-473, 2009.
2. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38 (4), 521-528, 2004.
3. Chuard C., Herrmenn M., Vaudaux P., Waldvogel F.A., Lew D.P. Successful therapy of experimental chronic foreign body infection due to methicillin resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35, 2611-2616, 1991.
4. Falagas M.E., Manta K.G., Ntziora F., Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. 58 (2), 273-280, 2006. (Pubitemid 44313381)
5. Chesi G., Colli A., Mestres C.A., Gambarati G., Boni F., Gherli T. Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. BMC Infect. Dis. 6, 124, 2006.
6. Drew R.H., Perfect J.R., Srinath L., Kurkimilis E., Dowzicky M., Talbot G.H. Treatment of methicillinresistant Staphylococcus aureus infections with quinupristin- dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J. Antimicrob. Chemother. 46 (5), 775-784, 2000.
7. Markowitz N., Quinn E.L., Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117 (5), 390-398, 1992.
8. Riedel D.J., Weekes E., Forrest G.N. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob. Agents Chemother. 52 (7), 2463-2467, 2008. (Pubitemid 351915676)
9. Small P.M., Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34 (6), 1227-1231, 1990 (Pubitemid 20177385)
10. LaPlante K.L, Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48 (12), 4665-4672, 2004.
11. Soriano A., Marco F., Martínez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46 (2), 193-200, 2008. (Pubitemid 351269157)
12. Fowler V.G. Jr, Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 17, 355 (7), 653-665, 2006.
13. Rehm S.J. Boucher H., Levine D., et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J. Antimicrob. Chemother. 62 (6), 1413-1421, 2008.
14. McCalla C., Smyth D.S., Robinson D.A., et al. Microbiological and genotypic analysis of methicillin- resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 52 (9), 3441-3443, 2008.
15. Levine D.P., Lamp K.C. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am. J. Med. 120 (10 Suppl 1), S28-S33, 2007.
16. Boucher H.W., Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45 (5), 601-608, 2007. (Pubitemid 47328642)
17. Sakoulas G., Golan Y., Lamp K.C., Friedrich L.V., Russo R. Daptomycin in the treatment of bacteremia. Am. J. Med. 120 (10 Suppl 1), S21-S7, 2007.
18. Julian K., Kosowska-Shick K., Whitener C., et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51 (9), 3445-3448, 2007.
19. Sieradzki K., Leski T., Dick J., Borio L., Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. Clin. Microbiol. 41 (4), 1687-1693, 2003.
20. Mwangi M.M., Wu S.W., Zhou Y., et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U.SA. 29, 104 (22), 9451-9456, 2007.
21. Friedman L., Alder J.D., Silverman J.A. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (6), 2137-2145, 2006. (Pubitemid 43807536)
22. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50 (3), 1079-1082, 2006. (Pubitemid 43327815)
23. Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50 (10), 3245-3249, 2006. (Pubitemid 44527494)
24. Credito K., Lin G., Appelbaum P.C. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob. Agents Chemother. 51 (4), 1504-1507, 2007. (Pubitemid 46586838)
25. Baltch A.L., Ritz W.J., Bopp L.H., Michelsen P.B., Smith R.P. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother. 51 (4), 1559-1562, 2007.
26. Rand K.H., Houck H.J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48 (8), 2871-2875, 2004.
27. Vouillamoz J., Moreillon P., Giddey M., Entenza J.M. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J. Antimicrob. Chemother. 58 (6), 1208-1214, 2006. (Pubitemid 44884140)
28. Levine D., Lamp K.C. Daptomycin experience for enterococcal endocarditis from a registry. In Abstracts of the 9th International Symposium of Modern Concepts in Endocarditis and Cardiovascular Infections, Organized on behalf of the International Society of Cardiovascular Infectious Diseases (ISCVID) June 14-17, 2007, Heidelberg, Germany.
29. Stevens M.P., Edmond M.B. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin. Infect. Dis. 41 (8), 1134-1142, 2005. (Pubitemid 41429476)
30. Raad I., Hanna H., Jiang Y., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51 (5), 1656-1660, 2007.
31. Edmiston C.E. Jr, Goheen M.P., Seabrook G.R., et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am. J. Surg. 192 (3), 344-354, 2006.